CG Oncology, Inc. (CGON)
Nasdaq: CGON · Biological Products, (No Diagnostic Substances) · Irvine, CA · filing with the SEC since 2023
Who owns CG Oncology, Inc.
As filed with the SECHolders of 5% or more
8
RTW Investments, LP holds 9.7% of Common Stock, $0.0001 par value, as its SCHEDULE 13G/A filed Aug 14, 2026 says.
Directors and officers
14
report now, of 15 people on the record since 2024. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 8 named at left.
Holders of 5% or moreshare of the class, as filed
RTW Investments, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value · 8.3% in May 15, 2026
Xiangmin Cui
SCHEDULE 13G/A · filed Feb 14, 2025 · Common stock, $0.0001 par value per share
T. Rowe Price Investment Management, Inc.
SCHEDULE 13G · filed May 15, 2026 · COMMON STOCK
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 27, 2026 · Common Stock
Wellington Management Group LLP
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock · 7.2% in Nov 12, 2025
Patrick G. Enright
SCHEDULE 13D · filed Sep 18, 2025 · Common Stock, $0.0001 par value per share
SONG, Hong Fang
SCHEDULE 13G/A · filed Jan 28, 2025 · Common stock, $0.0001 par value per share
Fmr LLC
SCHEDULE 13G · filed Aug 6, 2025 · COMMON STOCK
James B. Tananbaum
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 · reported falling below 5%
TCG Crossover GP I, LLC
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
Brian Liu
SCHEDULE 13D/A · filed Oct 28, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
Brian Liu
SCHEDULE 13D · filed Sep 18, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 8.62% in Oct 30, 2025
What CGON reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Biovire
A company bought · acquisition · Jul 2025 · owns, named in the 10-K filed Feb 27, 2026
3 subsidiaries in 1 country, from the list filed with the 10-K filed Feb 27, 2026.
Insider tradesForm 4
17sales
1purchases
17sales on a scheduled plan
2people selling
$4.8Msold, in dollars
$24.8Mbought, in dollars
Open-market trades on Form 4 from Oct 19, 2025 to Oct 19, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 19, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window3 of 28 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Mulay James | director | 8 | $3.8M | 8 | 0 | $0 |
| Post Leonard E | director | 9 | $1.1M | 9 | 0 | $0 |
| Liu Brian Guan-Chyun | director | 0 | $0 | 0 | 1 | $24.8M |